{"id":44345,"date":"2022-05-25T18:01:33","date_gmt":"2022-05-25T16:01:33","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-preclinical-cro-market-report-2022-2030-toxicology-testing-bioanalysis-dmpk-studies-rising-rd-offshoring-outsourcing-trends-researchandmarkets-com\/"},"modified":"2022-05-25T18:01:33","modified_gmt":"2022-05-25T16:01:33","slug":"global-preclinical-cro-market-report-2022-2030-toxicology-testing-bioanalysis-dmpk-studies-rising-rd-offshoring-outsourcing-trends-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-preclinical-cro-market-report-2022-2030-toxicology-testing-bioanalysis-dmpk-studies-rising-rd-offshoring-outsourcing-trends-researchandmarkets-com\/","title":{"rendered":"Global Preclinical CRO Market Report 2022-2030: Toxicology Testing, Bioanalysis & DMPK Studies – Rising R&D Offshoring & Outsourcing Trends – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Preclinical CRO Market Size, Share & Trends Analysis Report by Service (Toxicology Testing, Bioanalysis & DMPK Studies), by End Use (Biopharmaceutical Companies, Government & Academic Institutes), and Segment Forecasts, 2022-2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global preclinical CRO market size is expected to reach USD 9.67 billion by 2030, expanding at a CAGR of 7.9%.\n<\/p>\n

\nThe market is expected to show lucrative growth due to increasing R&D expenditure and rising outsourcing trends. The increasing volume of new drugs entering the preclinical phase is also anticipated to boost the market during the forecast period. However, the COVID-19 pandemic had temporarily affected the market owing to the shutdown of research sites due to the implementation of national lockdowns.\n<\/p>\n

\nThe market is undergoing a series of mergers and acquisitions, resulting in improvement in full-service capabilities and the international reach of larger companies. For instance, in 2019, WuXi AppTec acquired Pharmapace. On the other hand, mid-sized and smaller contract research organizations are focusing on niche sectors and are providing a personalized approach to their sponsors.\n<\/p>\n

\nVarious companies are focusing on research and development of new drugs and therefore are outsourcing these activities to launch efficient CRO services in the market. This, in turn, provides a positive atmosphere for joint ventures among market participants owing to the preference of sponsors to maximize their benefits.\n<\/p>\n

\nThe COVID-19 pandemic is ever increasing since the disease was first identified in China in December 2019. Until March 9, 2022, more than 4500 million cases of COVID-19 were reported globally; this pandemic has fast-tracked the development of vaccines and drug testing. There are currently over 195 COVID-19 vaccine candidates in preclinical studies.\n<\/p>\n

\nPreclinical CRO Market Report Highlights<\/strong>\n<\/p>\n